PT-141 (Bremelanotide)

What PT-141 (Bremelanotide) is

PT-141, formally known as bremelanotide and marketed as Vyleesi, is a synthetic cyclic heptapeptide with the chemical sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH ^[1]. It belongs to the melanocortin receptor agonist drug class and is classified by the WHO with the ATC code G02CX05 ^[2]. Unlike most compounds studied for sexual dysfunction, PT-141 is centrally acting — it engages melanocortin receptors in the brain rather than targeting peripheral vascular pathways ^[3].

The compound's origins trace back to Melanotan II (MT-II), a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) originally studied in the 1990s as a potential sunless tanning agent ^[4]. During early clinical investigations of MT-II, researchers observed an unexpected side effect: participants reported spontaneous erections and heightened sexual thoughts ^[5]. This serendipitous finding prompted scientists at Palatin Technologies to isolate the arousal-linked component of the molecule, ultimately producing the truncated heptapeptide now known as bremelanotide ^[5]. The systematic removal of specific amino acid residues from MT-II's structure enhanced the new compound's selectivity for MC3R and MC4R — the receptors implicated in sexual behavior — while reducing activity at MC1R, which is responsible for skin pigmentation ^[6]. Melanotan II development for sexual dysfunction was subsequently abandoned in 2000 in order to pursue bremelanotide ^[7].

What it is being researched for

1. Hypoactive Sexual Desire Disorder (HSDD) in Women

The most extensively researched application of bremelanotide is in premenopausal women diagnosed with acquired, generalized HSDD — a condition characterized by persistently diminished sexual desire causing personal distress. Two identical Phase 3 randomized, double-blind, placebo-controlled, multicenter trials (the RECONNECT studies) evaluated the compound's efficacy in 1,267 premenopausal women over 24 weeks ^[8]. Both studies demonstrated statistically significant improvements in sexual desire scores and reductions in desire-related distress compared to placebo ^[8]. An exit survey conducted after the RECONNECT trials found that participants who received bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in the overall quality of their sexual activities ^[9]. An open-label extension of the RECONNECT studies further demonstrated the long-term safety of bremelanotide in women with HSDD for up to 76 weeks ^[10].

2. Male Erectile Dysfunction and Sexual Dysfunction

Bremelanotide was also studied extensively in men with erectile dysfunction (ED) prior to its approval for HSDD. A review of centrally acting agents noted that bremelanotide demonstrated the potential to improve erectile function in men, and was considered a candidate for men who fail or cannot use phosphodiesterase type 5 (PDE5) inhibitors ^[11]. A randomized, double-blind, placebo-controlled study in men with sildenafil-failure ED found that bremelanotide produced a positive clinical response — defined as improved erections sufficient for intercourse — in approximately 33.5% of participants compared to 8.5% in the placebo group, a statistically significant difference ^[12]. Real-world clinical data from a sexual medicine clinic over 46 months found that among men prescribed bremelanotide off-label, 70% reported that their sexual function was at least 'a little better' based on a validated improvement scale, with improvements noted across erectile dysfunction, HSDD, and sexual performance anxiety ^[13].

3. Neuroimaging and Brain Pathway Mapping

An important research frontier for PT-141 is the use of functional MRI (fMRI) to map how melanocortin receptor agonism alters brain activity during sexual stimulation. A clinical study using bremelanotide as an MC4R agonist tool demonstrated a significant increase in participant-reported sexual desire compared with placebo up to 24 hours after administration, with brain imaging results consistent with those seen in the Phase 3 RECONNECT trials ^[14]. Separately, fMRI research showed that compared to placebo, bremelanotide improved connectivity between the amygdala and the insula during visual sexual stimulation, enhanced cerebellar and supplementary motor area activity, and deactivated the secondary somatosensory cortex ^[15]. Ongoing registered clinical trials are using fMRI with visual erotic stimuli to measure how bremelanotide modulates the central melanocortin system in women with HSDD ^[16].

4. Preclinical CNS and Animal Models

Preclinical studies in rodent models played a foundational role in characterizing bremelanotide's central effects on sexual behavior. Research by Pfaus et al. showed that bremelanotide dramatically and selectively increased measures of sexual solicitation in female rats without altering pacing or lordosis behaviors — effects observed following both peripheral administration and direct infusions into the medial preoptic area (mPOA) of the hypothalamus ^[17]. The mPOA is considered critical for the display of appetitive sexual behaviors across multiple species ^[17]. Animal studies also suggest that bremelanotide may affect sexual desire by activating presynaptic MC4Rs on neurons in the mPOA, leading to increased release of dopamine — an excitatory neurotransmitter that modulates motivation and desire ^[18]. These preclinical findings provided the mechanistic rationale for translational research into human sexual dysfunction ^[17].

5. Melanocortin System Pharmacology and Structure-Activity Research

PT-141's well-characterized pharmacological profile makes it a valued tool compound for basic receptor pharmacology research. It is studied as an agonist of the melanocortin receptor family — a set of five G-protein-coupled receptors (MC1R–MC5R) — with particular interest in its selectivity for the MC3R and MC4R subtypes that are densely expressed in the central nervous system ^[3]. The cyclic lactam bridge that defines PT-141's heptapeptide structure is a key structure-activity feature: by constraining the peptide backbone into a ring, it pre-organizes the His-Phe-Arg-Trp core pharmacophore for receptor engagement ^[3]. Researchers use PT-141 experimentally to interrogate how central melanocortin signaling propagates through the brain, distinguishing these central actions from peripheral melanocortin effects on pigment cells or the adrenal cortex ^[3]. The POMC-derived peptide system — including α-MSH, β-MSH, γ-MSH, and ACTH — provides the endogenous context within which PT-141's agonism is studied ^[6].

6. Safety, Tolerability, and Cardiovascular Effects

A comprehensive safety analysis of the bremelanotide clinical development program, which encompassed approximately 3,500 subjects across 43 completed studies, identified nausea, flushing, headache, and injection-site reactions as the most common adverse events ^[19]. Nausea — occurring in approximately 40% of bremelanotide-treated participants vs. 1.3% placebo — was the most frequent reason for discontinuation, though the incidence declined with subsequent use ^[19]. Studies using ambulatory blood pressure monitoring found small, transient increases in blood pressure peaking within 4 hours post-exposure and returning toward baseline by approximately 8–10 hours, with no cumulative effect observed on blood pressure or heart rate over consecutive days of monitoring ^[10]. Focal hyperpigmentation was rare when bremelanotide was used in accordance with label recommendations, but occurred more frequently with consecutive daily use ^[19]. These findings led regulators to recommend caution in individuals with cardiovascular disease or uncontrolled hypertension ^[20].

7. Comparison with PDE5 Inhibitor Mechanisms

A recurring theme in bremelanotide research is its mechanistic contrast with phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil. While PDE5 inhibitors act peripherally by inhibiting an enzyme in vascular tissue to alter local blood flow, bremelanotide operates centrally by engaging brain melanocortin receptors, making the two classes mechanistically distinct ^[6]. This central mechanism generates both the psychological component of desire and downstream physiological arousal responses ^[6]. Clinical interest in this distinction is particularly relevant in the context of men with sildenafil-failure ED, where a randomized controlled trial showed that bremelanotide produced meaningful improvements in erectile function in some patients who had not responded to PDE5 inhibitor therapy ^[12]. Preclinical and clinical research confirmed that melanocortin receptor agonists improve sexual function via central action, particularly within the hypothalamus, adding a separate pharmacological option to the sexual dysfunction treatment landscape ^[20].

How it is thought to work

PT-141 (bremelanotide) is a melanocortin receptor agonist — a molecule that binds to and activates members of the melanocortin receptor family, a group of five G-protein-coupled receptors (MC1R through MC5R). Its primary pharmacological activity is directed at MC3R and MC4R, which are densely concentrated in the hypothalamus and limbic structures of the brain, including the medial preoptic area (mPOA), paraventricular nucleus (PVN), amygdala, and nucleus accumbens ^[1][3][6]. When PT-141 activates MC4R — a Gs-coupled receptor — it triggers adenylyl cyclase, raising intracellular cyclic AMP (cAMP), which in turn modulates neuronal excitability and signaling in circuits governing sexual desire, arousal, and motivation ^[3]. Animal studies suggest that this MC4R activation in the mPOA also stimulates downstream dopaminergic signaling in mesolimbic reward circuits, and that it is this MC4R–dopamine interaction that provides the mechanistic link between melanocortin activation and the subjective experience of sexual arousal ^[6][18].

This central, neurologically-driven mechanism is what investigators frequently distinguish from the peripheral vascular mechanism of PDE5 inhibitors. Rather than acting on blood vessel enzyme activity, PT-141 engages upstream brain processes — the desire and motivational circuitry — that initiate sexual response at the neurological level ^[6]. Functional MRI studies have provided in vivo evidence for this, showing that MC4R agonism with bremelanotide improves connectivity between the amygdala and the insula during visual sexual stimulation, enhances activity in brain regions associated with motor planning and arousal, and modulates somatosensory cortex activity compared to placebo ^[15]. The peptide's cyclic lactam structure constrains the backbone to pre-organize the core pharmacophore for selective receptor engagement, distinguishing it structurally and functionally from its precursor, Melanotan II ^[3].

Where the evidence stands

The evidence base for bremelanotide spans preclinical animal models, early-phase human studies, and large randomized controlled trials. In preclinical work, rodent studies demonstrated that bremelanotide selectively increased appetitive (solicitation) sexual behaviors in female rats through actions on the mPOA and connected limbic circuitry, providing the neuroanatomical and pharmacological rationale for its investigation in humans ^[17]. Early human studies showed that women with sexual arousal disorder reported increased subjective sexual desire and more positive genital arousal responses compared to placebo, with statistically significant differences on desire measures ^[8]. The pivotal human evidence comes from the RECONNECT Phase 3 program, two identical randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD over 24 weeks, which demonstrated statistically significant improvements in sexual desire and reductions in desire-related distress ^[8]. These results led to FDA approval of bremelanotide as Vyleesi in 2019 ^[2]. An open-label extension study further characterized the long-term safety profile out to 76 weeks ^[10].

Despite this substantial body of evidence, important limitations and gaps remain. The Phase 3 RECONNECT trials were conducted almost exclusively in premenopausal women at U.S. sites, limiting generalizability to other populations including postmenopausal women, men, or more ethnically diverse cohorts ^[8]. While Phase 2 studies were conducted in men with ED, bremelanotide remains unapproved for male sexual dysfunction, and real-world data in men derive from relatively small, single-clinic observational studies ^[13]. The magnitude of improvement on primary efficacy endpoints in the Phase 3 trials, while statistically significant, was modest, and critics note that the clinical meaningfulness of the effect size warrants continued scrutiny ^[20]. Adverse effects — particularly a 40% incidence of nausea and transient blood pressure elevations — represent meaningful tolerability challenges that contributed to discontinuation in a subset of participants ^[19]. The neuroimaging evidence for bremelanotide's central mechanism is promising but still emerging, with registered fMRI trials ongoing to better characterize the specific brain circuits involved ^[16].

Frequently asked questions

What is PT-141 and how is it different from Viagra?

PT-141 (bremelanotide) is a synthetic peptide that acts on melanocortin receptors in the brain to influence sexual desire and arousal through central nervous system pathways. Viagra (sildenafil) is a PDE5 inhibitor that works peripherally by altering blood flow in genital tissue. The two compounds have entirely different mechanisms — PT-141 targets the neurological desire circuitry, while sildenafil targets vascular enzyme activity. This mechanistic distinction is a primary reason PT-141 has been researched in patients who do not respond to PDE5 inhibitors.

Is bremelanotide FDA approved?

Yes. Bremelanotide was approved by the FDA in 2019 under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is currently the only FDA-approved melanocortin receptor agonist for this indication. It is not FDA-approved for use in men or postmenopausal women, though off-label research and clinical use exist.

What receptors does PT-141 target?

PT-141 is a non-selective melanocortin receptor agonist with highest affinity for the MC4R and MC3R subtypes, both of which are densely expressed in the hypothalamus and limbic regions of the brain. Activation of MC4R, a Gs-coupled receptor, triggers intracellular cAMP signaling in neurons involved in sexual desire and arousal. Its reduced activity at MC1R — the receptor responsible for skin pigmentation — was a deliberate design feature distinguishing it from its precursor, Melanotan II.

What were the main findings from the RECONNECT clinical trials?

The RECONNECT trials were two identical Phase 3 randomized, double-blind, placebo-controlled studies enrolling 1,247 premenopausal women with HSDD over 24 weeks. Both studies showed statistically significant increases in sexual desire scores and reductions in sexual desire-related distress compared to placebo. Patient exit surveys found that women who received bremelanotide also described improvements in physical arousal and overall sexual activity quality.

What are the known side effects of bremelanotide?

Across 43 clinical studies involving approximately 3,500 subjects, the most commonly reported adverse events were nausea (approximately 40%), flushing (approximately 20%), headache (approximately 11%), and injection site reactions. Nausea was the most frequent reason for discontinuation, though its incidence typically declined with repeated use. Small, transient increases in blood pressure were also observed, which is why bremelanotide is contraindicated in individuals with uncontrolled hypertension or known cardiovascular disease.

How was PT-141 discovered?

PT-141's discovery was largely serendipitous. In the 1990s, researchers studying Melanotan II as a potential sunless tanning agent observed an unexpected side effect — participants reported spontaneous erections and heightened sexual thoughts. Scientists subsequently worked to isolate the part of the Melanotan II molecule responsible for these arousal effects. Through systematic removal of specific amino acid residues, they produced a truncated heptapeptide with enhanced selectivity for MC3R and MC4R over MC1R (the pigmentation receptor), and this compound became bremelanotide (PT-141).

Has PT-141 been studied in men?

Yes. Phase 2 randomized controlled trials investigated bremelanotide in men with erectile dysfunction, including those who had not responded to sildenafil. One study in sildenafil-failure ED found that bremelanotide produced a positive clinical response — improved erections sufficient for intercourse — in approximately 33.5% of treated participants versus 8.5% on placebo. Real-world clinical data from a sexual medicine clinic also reported improvements in erectile dysfunction, low sexual desire, and sexual performance anxiety in men prescribed bremelanotide off-label. However, bremelanotide is not currently FDA-approved for male sexual dysfunction.

What does bremelanotide do in the brain?

Bremelanotide activates MC4R and MC3R receptors in key brain regions including the medial preoptic area (mPOA) and paraventricular nucleus of the hypothalamus, the amygdala, and the nucleus accumbens. This receptor activation stimulates downstream dopaminergic signaling in the brain's mesolimbic reward circuits, which researchers associate with the motivational and desire-related aspects of sexual arousal. Functional MRI studies have shown that MC4R agonism with bremelanotide improves connectivity between the amygdala and insula during visual sexual stimulation and enhances activity in multiple brain regions compared to placebo.

Is PT-141 approved or regulated in Canada?

As of the current research landscape, bremelanotide (Vyleesi) holds FDA approval in the United States for HSDD in premenopausal women, but does not hold a Health Canada drug identification number (DIN) for sale as a prescription drug in Canada. Researchers and regulatory professionals should consult Health Canada directly for the most current status. PT-141 is available from Canadian research peptide suppliers strictly for research and laboratory use, not for human therapeutic application.

What is the difference between PT-141 and Melanotan II?

Both PT-141 (bremelanotide) and Melanotan II are synthetic analogs of α-MSH and melanocortin receptor agonists, but they differ in structure, receptor selectivity, and regulatory status. Melanotan II is a full-length cyclic heptapeptide that potently activates MC1R (pigmentation), MC3R, MC4R, and MC5R — contributing to both skin tanning and sexual effects. PT-141 was engineered from Melanotan II through structural modifications that reduced MC1R activity, minimizing tanning effects while preserving the MC3R/MC4R agonism associated with sexual function. Melanotan II is not FDA-approved; bremelanotide is FDA-approved as Vyleesi for HSDD.

Glossary

Melanocortin receptor (MCR)

A family of five G-protein-coupled receptors (MC1R–MC5R) activated by peptides derived from the proopiomelanocortin (POMC) protein, regulating diverse functions including pigmentation, energy balance, and sexual behavior.

MC4R (Melanocortin-4 receptor)

A Gs-coupled G-protein-coupled receptor expressed densely in the hypothalamus and limbic brain regions; considered the primary receptor mediating bremelanotide's effects on sexual desire and arousal.

Hypoactive Sexual Desire Disorder (HSDD)

A clinical condition characterized by persistently low or absent sexual desire that causes personal distress, and which is the primary approved indication for bremelanotide (Vyleesi) in premenopausal women.

Cyclic heptapeptide

A peptide consisting of seven amino acids linked in a ring (cyclic) structure, where PT-141's lactam bridge constrains the backbone to enhance receptor binding selectivity.

PDE5 inhibitor

A class of drugs (e.g., sildenafil/Viagra) that act peripherally by inhibiting the enzyme phosphodiesterase type 5 to increase blood flow in genital tissue, mechanistically distinct from centrally-acting compounds like bremelanotide.

Medial preoptic area (mPOA)

A region of the hypothalamus that is critical for the expression of appetitive sexual behaviors in both males and females, and a key site of bremelanotide's central MC4R-mediated action.

Proopiomelanocortin (POMC)

A precursor protein in the brain and pituitary gland that is cleaved into multiple biologically active peptides including α-MSH, β-MSH, γ-MSH, and ACTH, all of which activate melanocortin receptors.

Alpha-melanocyte-stimulating hormone (α-MSH)

An endogenous neuropeptide derived from POMC that activates melanocortin receptors and serves as the natural template from which synthetic analogs including Melanotan II and bremelanotide were designed.

References

1. Bremelanotide — Drug Summary and Identifiers — Wikipedia (citing DrugBank DB11653, PubChem CID 9941379, WHO ATC G02CX05)
2. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder — Annals of Pharmacotherapy, 2020
3. PT-141 (Bremelanotide): Melanocortin Receptor Research — MC4R Signaling, CNS Pharmacology & Structure-Activity — NST Research
4. Melanotan II — Wikipedia (development history) — Wikipedia
5. Bremelanotide: From Tanning Peptide to Cutting-Edge Arousal Therapy — Shameless Care
6. PT-141 (Bremelanotide): Complete Research Guide — Path to Peptides
7. Melanocortin 4 Receptor — Wikipedia — Wikipedia
8. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT) — Obstetrics & Gynecology (PubMed PMID 31599840)
9. The Patient Experience of Premenopausal Women Treated with Bremelanotide for HSDD: RECONNECT Exit Study Results — Journal of Women's Health (PubMed PMID 33538638)
10. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder — Obstetrics & Gynecology
11. Central Nervous System Agents and Erectile Dysfunction — PubMed (PMID 21621083)
12. Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled Study — The Journal of Urology, 2008
13. Use of Bremelanotide in Men with Sexual Dysfunction at a Sexual Medicine Clinic — The Journal of Sexual Medicine, 2024
14. Melanocortin 4 Receptor Agonism Enhances Sexual Brain Processing in Women with Hypoactive Sexual Desire Disorder — Journal of Clinical Investigation
15. Use of the CNS Agent Bremelanotide in Men with Sexual Dysfunction: Results from a Sexual Medicine Clinic (fMRI data cited) — The Journal of Sexual Medicine, 2024